GHRP-6 vs Hexarelin: GH Secretagogue Comparison

Aged C57BL/6 mice (18-24 months) represent the most translational model for ipamorelin bone research: somatopause (GH/IGF-1 decline with age) mirrors human ageing-associated GH secretory dysfunction and the resultant age-related bone loss. Ipamorelin (100-300 μg/kg s.c. twice daily × 8-16 weeks) in aged cohorts: primary endpoints — serum IGF-1 ELISA (confirming GH axis restoration), micro-CT distal femur trabecular (BV/TV, Tb.N, Tb.Th, Tb.Sp, Conn.D, SMI) and midshaft cortical (Ct.Th, Ct.TMD, J polar moment), dynamic histomorphometry (calcein 15 mg/kg day -14 + alizarin red 30 mg/kg day -7, undecalcified methylmethacrylate, MAR-BFR/BS-MS/BS), bone turnover serology (P1NP formation, CTX-I resorption), and 3-point bending biomechanics (Lloyd Instruments TA.XT, 10 mm span, 0.5 mm/s displacement, ultimate load, stiffness, toughness, post-yield displacement). Young adult (3-4 month) cohort run in parallel as the reference phenotype. OVX model (bilateral ovariectomy, 12-week C57BL/6 females): estrogen deficiency produces rapid trabecular bone loss (-40-50% BV/TV within 8 weeks). Ipamorelin treatment initiated at 8 weeks post-OVX (established osteoporosis), 4-week treatment phase (weeks 8-12). GH/IGF-1 axis restoration in the estrogen-deficient context: E2 normally potentiates hepatic GH receptor signalling via estrogen response elements in GHR and IGFBP-3 promoters — OVX reduces IGF-1 despite normal GH pulse frequency, positioning ipamorelin-driven GH pulse amplitude augmentation as a compensatory anabolic strategy. Zoledronic acid (100 μg/kg single i.v.) anti-resorptive comparator and teriparatide (40 μg/kg/day s.c.) anabolic comparator establish the pharmacological context for ipamorelin’s mechanism — with ipamorelin expected to increase both P1NP and modestly reduce CTX-I (contrasting with bisphosphonate-alone anti-resorptive profile).

Hexarelin GHSR-1a and CD36 Research: GH Secretagogue Receptor Pharmacology Research Overview Hexarelin represents a synthetic hexapeptide compound extensively investigated in cell-based assay formats for its dual receptor pharmacology profile. This research peptide demonstrates selective agonism at the growth hormone secretagogue receptor type 1a (GHSR-1a) and exhibits ligand activity at the CD36 scavenger receptor. Published in vitro studies characterize its molecular interactions, binding affinity profiles, and downstream pathway engagement in defined cell model systems under controlled laboratory conditions. The compound's unique pharmacological profile makes it valuable for investigating receptor-mediated signaling cascades and cellular response mechanisms in cardiovascular and endocrine cell models. Receptor Pharmacology and Mechanism of Action GHSR-1a Receptor Interactions Hexarelin functions as a selective agonist at the GHSR-1a receptor, a G-protein coupled receptor (GPCR) belonging to the ghrelin receptor family. In vitro binding assays demonstrate high affinity interactions with GHSR-1a, exhibiting nanomolar range binding constants in competitive displacement studies. The compound activates Gq/11-mediated signaling pathways, resulting in phospholipase C activation and subsequent inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG) generation. Calcium mobilization assays in GHSR-1a-expressing cell lines reveal robust intracellular calcium release following hexarelin exposure. The peptide demonstrates concentration-dependent receptor activation with EC50 values typically ranging from 10-100 nanomolar in functional assays. Signal transduction studies indicate sustained activation of protein kinase C (PKC) isoforms and downstream effector molecules involved in cellular response regulation. CD36 Receptor Ligand Activity Beyond GHSR-1a interactions, hexarelin exhibits binding activity at the CD36 scavenger receptor, a transmembrane glycoprotein involved in lipid recognition and cellular uptake mechanisms. Surface plasmon resonance studies confirm direct binding interactions between hexarelin and CD36 receptor domains. This interaction represents a distinct pharmacological pathway independent of GHSR-1a-mediated effects. CD36 binding assays demonstrate moderate affinity interactions, with dissociation constants in the micromolar range. The compound's interaction with CD36 receptors triggers alternative signaling cascades involving src-family kinases and focal adhesion kinase (FAK) phosphorylation pathways. Signaling Pathway Analysis PI3K/AKT Pathway Activation Hexarelin treatment in cell culture models consistently activates the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) signaling pathway. Western blot analysis reveals time-dependent phosphorylation of AKT at both Ser473 and Thr308 residues following peptide exposure. This activation occurs through both GHSR-1a-dependent and CD36-mediated mechanisms, suggesting convergent signaling pathway regulation. Pathway inhibitor studies using specific PI3K antagonists demonstrate reduced AKT phosphorylation, confirming the involvement of PI3K upstream signaling. Downstream targets of AKT activation include glycogen synthase kinase-3β (GSK-3β) and mammalian target of rapamycin (mTOR), which exhibit increased phosphorylation status in hexarelin-treated cell cultures. MAPK Cascade Engagement Mitogen-activated protein kinase (MAPK) pathway analysis reveals hexarelin-induced activation of extracellular signal-regulated kinases (ERK1/2). Immunoblotting studies demonstrate phosphorylation of ERK1/2 within 15-30 minutes of peptide exposure in various cell models. This activation appears primarily mediated through GHSR-1a receptor engagement and subsequent PKC-dependent signaling. Cardiovascular Cell Model Applications Cardiomyocyte Culture Studies Primary cardiomyocyte cultures provide valuable models for investigating hexarelin's cardiac-specific receptor pharmacology. These cell systems express both GHSR-1a and CD36 receptors, enabling comprehensive analysis of the compound's dual receptor targeting effects. Contractility assays in cultured cardiomyocytes demonstrate enhanced calcium handling and improved cellular viability parameters following hexarelin treatment. Endothelial Cell Investigations Human umbilical vein endothelial cell (HUVEC) models reveal hexarelin's effects on vascular cell function through CD36 and GHSR-1a receptor interactions. Angiogenesis assays, including tube formation and migration studies, demonstrate enhanced endothelial cell responses in the presence of hexarelin. These effects correlate with increased nitric oxide production and improved endothelial barrier function in cell culture systems. Enzyme Kinetics and Binding Affinity Studies Detailed pharmacokinetic analysis reveals hexarelin's binding characteristics across multiple receptor targets. Scatchard plot analysis indicates single-site binding at GHSR-1a receptors with Kd values ranging from 5-50 nanomolar depending on cell model systems. CD36 binding exhibits lower affinity but demonstrates significant biological activity at micromolar concentrations. Competition binding studies using radiolabeled hexarelin confirm receptor selectivity profiles and identify potential allosteric binding sites. These investigations provide crucial data for understanding structure-activity relationships and optimizing experimental protocols for cell-based assays. Research Summary Hexarelin demonstrates complex receptor pharmacology through dual targeting of GHSR-1a and CD36 receptors in cell culture models. The compound activates multiple signaling pathways including PI3K/AKT and MAPK cascades, providing valuable tools for investigating receptor-mediated cellular responses. Its applications in cardiovascular cell models offer insights into receptor biology and signaling mechanism research, making it a useful compound for in vitro pharmacological investigations. All content is intended for in vitro laboratory research purposes only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any condition. Hexarelin TB-500 Epithalon Ipamorelin Tirzepatide CJC-1295 DAC PT-141 Semaglutide Selank BPC-157 Sermorelin Melanotan 2 IGF LR3 Tesamorelin AICAR IGF-DES GHRP 2 Albuterol Tamoxifen Letrozole Clomiphene Tadalafil Clenbuterol Anastrozole Finasteride Exemestane Sildenafil Yohimbine Bacteriostatic Water Recent Posts Melanotan 2 (MT2): Mechanism, Research, and Safety Considerations Ipamorelin: The Selective GHRP, Explained Tesamorelin: The GHRH Analog Studied for Visceral Fat Sermorelin: The Original GHRH Analog, Explained CJC-1295: How the GHRH Analog Works, and What Research Shows Already a customer? Sign In Create Account All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease. ElementSarms is a chemical supplier. ElementSarms is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. ElementSarms is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act. Sarms Stacks Research Liquids Albuterol 5MG/ML | 30ML with dropper Anastrozole 1.5MG/ML | 30ML with dropper Clomiphene 50MG/ML | 30ML with dropper Finasteride 5MG/ML | 30ML with dropper Letrozole 3.5 MG/ML | 30ML with dropper LiquiCia 30MG/ML | 30ML with dropper LiquiCia T50 50MG/ML | 30ML with dropper LiquiClen 200MCG/ML | 30ML with dropper Liquistane / Exemestane 25MG/ML | 30ML with dropper LiquiTamo 20MG/ML | 30ML with dropper LiquiVia 25MG/ML | 30 ML with dropper T3 LIOTHYRONINE 200MCG/ML | 30ML with dropper Toremifene Citrate 60MG/ML | 30ML with dropper Yohimbine HCL 10MG/ML | 30ML with dropper Research Peptides Aicar 50MG BPC-157 + TB-500 Blend 2mg ea/ 4MG BPC-157 5MG CJC-1295 + DAC 2MG CJC-1295 | No DAC 2MG Epithalon 10MG Frag Premium 176-191 5MG GHK-CU Copper Peptide 50MG GHRP-2 5MG GHRP-6 5MG Hexarelin 5MG IGF-1 DES 1MG IGF-1 LR3 1MG Ipamorelin 5MG Melanotan 2 10MG NAD+ 500MG PT-141 / Bremelanotide 10MG GLP-1/GIP/GCG (RT) Selank 5MG GLP1 (SM) Sermorelin 5MG TB-500 5MG GIP/GLP-1 (TZ) PDE5 Inhibitors GLP-1 Diluents Bacteriostatic Water 10ML